NASDAQ:JNCE Jounce Therapeutics - JNCE Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Jounce Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $1.52 +0.04 (+2.70%) (As of 03/23/2023 12:00 AM ET) Add Compare Share Share Today's Range$1.47▼$1.5450-Day Range$0.90▼$1.6752-Week Range$0.58▼$7.94Volume1.29 million shsAverage Volume2.38 million shsMarket Capitalization$79.25 millionP/E RatioN/ADividend YieldN/APrice Target$6.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Jounce Therapeutics MarketRank™ ForecastAnalyst RatingHold2.40 Rating ScoreUpside/Downside294.7% Upside$6.00 Price TargetShort InterestBearish9.58% of Float Sold ShortDividend StrengthN/ASustainability-0.67Upright™ Environmental ScoreNews Sentiment-0.23Based on 2 Articles This WeekInsider TradingAcquiring Shares$65,044 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($1.01) to ($1.71) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.30 out of 5 starsMedical Sector226th out of 986 stocksBiological Products, Except Diagnostic Industry35th out of 165 stocks 3.2 Analyst's Opinion Consensus RatingJounce Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 2 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.00, Jounce Therapeutics has a forecasted upside of 294.7% from its current price of $1.52.Amount of Analyst CoverageJounce Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted9.58% of the float of Jounce Therapeutics has been sold short.Short Interest Ratio / Days to CoverJounce Therapeutics has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Jounce Therapeutics has recently increased by 202.17%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldJounce Therapeutics does not currently pay a dividend.Dividend GrowthJounce Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreJounce Therapeutics has received a 75.46% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health" and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Jounce Therapeutics is -0.67. Previous Next 2.1 News and Social Media Coverage News SentimentJounce Therapeutics has a news sentiment score of -0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.35 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Jounce Therapeutics this week, compared to 1 article on an average week.Search Interest32 people have searched for JNCE on MarketBeat in the last 30 days. This is an increase of 129% compared to the previous 30 days.MarketBeat Follows2 people have added Jounce Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Jounce Therapeutics insiders have bought 55.13% more of their company's stock than they have sold. Specifically, they have bought $65,044.00 in company stock and sold $41,929.00 in company stock.Percentage Held by InsidersOnly 6.92% of the stock of Jounce Therapeutics is held by insiders.Percentage Held by Institutions80.66% of the stock of Jounce Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Jounce Therapeutics are expected to decrease in the coming year, from ($1.01) to ($1.71) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Jounce Therapeutics is -0.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Jounce Therapeutics is -0.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioJounce Therapeutics has a P/B Ratio of 0.43. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Jounce Therapeutics (NASDAQ:JNCE) StockJounce Therapeutics, Inc. is a clinical stage immunotherapy company, which engages in developing treatments for cancer. It also provides novel cancer immunotherapies to attack tumors. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber, and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA.Read More Receive JNCE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Jounce Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address JNCE Stock News HeadlinesMarch 23, 2023 | benzinga.comMoore Kuehn Encourages JNCE, USX, INDT, and BHWB Investors to Contact Law FirmMarch 23, 2023 | americanbankingnews.comJounce Therapeutics (NASDAQ:JNCE) Stock Rating Lowered by StockNews.comMarch 23, 2023 | Behind the Markets (Ad)Buy THIS stock before Taiwan is attacked... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.March 17, 2023 | 247wallst.comTang Capital Partners Now Owns 10.2% of Jounce TherapeuticsMarch 16, 2023 | finance.yahoo.comJounce Therapeutics Announces Results from Pre-Planned Data Review of INNATE Phase 2 Trial of JTX-8064 and Pimivalimab Demonstrating Deep and Durable Responses in Platinum Resistant Ovarian CancerMarch 16, 2023 | finance.yahoo.comJounce (JNCE) Up 41% on Buyout Offer From Concentra BiosciencesMarch 16, 2023 | americanbankingnews.comKevin C. Tang Purchases 65,701 Shares of Jounce Therapeutics, Inc. (NASDAQ:JNCE) StockMarch 15, 2023 | benzinga.com10% Owner of Jounce Therapeutics Makes $85K BuyMarch 23, 2023 | Behind the Markets (Ad)Buy THIS stock before Taiwan is attacked... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.March 15, 2023 | finance.yahoo.comWhy Jounce Therapeutics Stock Is Moving Higher Today?March 15, 2023 | markets.businessinsider.comConcentra Biosciences Proposes To Acquire Jounce Therapeutics - Quick FactsMarch 15, 2023 | msn.comTang Capital Partners Now Owns 10.20% of Jounce Therapeutics (JNCE)March 15, 2023 | marketwatch.comJounce Therapeutics Jumps Premarket on Buyout Bid >JNCEMarch 15, 2023 | investorplace.comWhy Is Jounce Therapeutics (JNCE) Stock Up 37% Today?March 15, 2023 | americanbankingnews.comStockNews.com Upgrades Jounce Therapeutics (NASDAQ:JNCE) to "Buy"March 15, 2023 | finance.yahoo.comJounce Therapeutics Confirms Receipt of Unsolicited Proposal from Concentra BiosciencesMarch 13, 2023 | finance.yahoo.comJounce Therapeutics stock bounces after saying only 1.4% of its cash was in an SVB operating accountMarch 11, 2023 | finance.yahoo.comJounce Therapeutics Full Year 2022 Earnings: Beats ExpectationsMarch 1, 2023 | benzinga.comMoore Kuehn Encourages ROCC, JNCE, BRMK, and FOCS Investors to Contact Law FirmMarch 1, 2023 | benzinga.comJOUNCE THERAPEUTICS INVESTOR ALERT by the Former...February 23, 2023 | benzinga.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Jounce Therapeutics, Inc. MergerFebruary 23, 2023 | finance.yahoo.comCambridge biotech Jounce to cut staff, merge with U.K. drug developerFebruary 23, 2023 | finanznachrichten.deJounce Therapeutics, Inc.: Redx and Jounce Announce Recommended Business CombinationFebruary 23, 2023 | marketwatch.comJounce Shares Bounce Higher on Tie-Up With Redx >JNCEFebruary 23, 2023 | markets.businessinsider.comRaymond James downgrades Jounce Therapeutics (JNCE) to a HoldFebruary 23, 2023 | msn.comJounce stock soars ~35% on all-stock merger with Redx PharmaFebruary 23, 2023 | finance.yahoo.comRedx and Jounce Announce Recommended Business CombinationSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive JNCE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Jounce Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address JNCE Company Calendar Last Earnings11/04/2021Today3/23/2023Next Earnings (Estimated)3/29/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:JNCE CUSIPN/A CIK1640455 Webwww.jouncetx.com Phone(857) 259-3840FaxN/AEmployees137Year FoundedN/APrice Target and Rating Average Stock Price Forecast$6.00 High Stock Price Forecast$11.00 Low Stock Price Forecast$3.00 Forecasted Upside/Downside+294.7%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-50,920,000.00 Net MarginsN/A Pretax Margin-61.93% Return on Equity-30.90% Return on Assets-26.31% Debt Debt-to-Equity RatioN/A Current Ratio8.37 Quick Ratio8.37 Sales & Book Value Annual Sales$82 million Price / Sales0.97 Cash FlowN/A Price / Cash FlowN/A Book Value$3.54 per share Price / Book0.43Miscellaneous Outstanding Shares52,140,000Free Float48,532,000Market Cap$79.25 million OptionableOptionable Beta0.63 Key ExecutivesRichard MurrayPresident, Chief Executive Officer & DirectorKimberlee Cobleigh DrapkinChief Financial & Accounting Officer, TreasurerElizabeth G. TrehuChief Medical OfficerDmitri WiederschainChief Scientific OfficerStephen FarrandChief Technical OfficerKey CompetitorsAdverum BiotechnologiesNASDAQ:ADVMGreenLight BiosciencesNASDAQ:GRNAInstil BioNASDAQ:TILTalaris TherapeuticsNASDAQ:TALSMiNK TherapeuticsNASDAQ:INKTView All CompetitorsInsiders & InstitutionsKevin C TangBought 65,701 shares on 3/13/2023Total: $65,043.99 ($0.99/share)Voya Investment Management LLCBought 95,730 shares on 2/28/2023Ownership: 0.301%Millennium Management LLCBought 1,828,681 shares on 2/15/2023Ownership: 3.538%Morgan StanleySold 20,523 shares on 2/15/2023Ownership: 3.207%Squarepoint Ops LLCBought 35,606 shares on 2/15/2023Ownership: 0.069%View All Insider TransactionsView All Institutional Transactions JNCE Stock - Frequently Asked Questions Should I buy or sell Jounce Therapeutics stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Jounce Therapeutics in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" JNCE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in JNCE, but not buy additional shares or sell existing shares. View JNCE analyst ratings or view top-rated stocks. What is Jounce Therapeutics' stock price forecast for 2023? 5 brokerages have issued 1-year price targets for Jounce Therapeutics' stock. Their JNCE share price forecasts range from $3.00 to $11.00. On average, they expect the company's stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 294.7% from the stock's current price. View analysts price targets for JNCE or view top-rated stocks among Wall Street analysts. How have JNCE shares performed in 2023? Jounce Therapeutics' stock was trading at $1.11 on January 1st, 2023. Since then, JNCE shares have increased by 36.9% and is now trading at $1.52. View the best growth stocks for 2023 here. Are investors shorting Jounce Therapeutics? Jounce Therapeutics saw a increase in short interest in the month of February. As of February 28th, there was short interest totaling 4,170,000 shares, an increase of 202.2% from the February 13th total of 1,380,000 shares. Based on an average trading volume of 2,390,000 shares, the short-interest ratio is presently 1.7 days. Currently, 9.6% of the shares of the company are sold short. View Jounce Therapeutics' Short Interest. When is Jounce Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 29th 2023. View our JNCE earnings forecast. How were Jounce Therapeutics' earnings last quarter? Jounce Therapeutics, Inc. (NASDAQ:JNCE) posted its quarterly earnings data on Thursday, November, 4th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.44) by $0.15. During the same period in the prior year, the company posted ($0.73) earnings per share. What is Richard Murray Ph.D's approval rating as Jounce Therapeutics' CEO? 45 employees have rated Jounce Therapeutics Chief Executive Officer Richard Murray Ph.D on Glassdoor.com. Richard Murray Ph.D has an approval rating of 97% among the company's employees. This puts Richard Murray Ph.D in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Jounce Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Jounce Therapeutics investors own include Exelixis (EXEL), Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), CRISPR Therapeutics (CRSP), Novavax (NVAX), Mylan (MYL), Progenics Pharmaceuticals (PGNX), Adaptimmune Therapeutics (ADAP), Incyte (INCY) and Nektar Therapeutics (NKTR). When did Jounce Therapeutics IPO? (JNCE) raised $76 million in an initial public offering (IPO) on Friday, January 27th 2017. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan and Cowen and Company acted as the underwriters for the IPO and Wells Fargo Securities and Baird were co-managers. What is Jounce Therapeutics' stock symbol? Jounce Therapeutics trades on the NASDAQ under the ticker symbol "JNCE." Who are Jounce Therapeutics' major shareholders? Jounce Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Bank of America Corp DE (6.34%), Millennium Management LLC (3.54%), Morgan Stanley (3.21%), Dimensional Fund Advisors LP (1.38%), Geode Capital Management LLC (1.30%) and Assenagon Asset Management S.A. (1.01%). Insiders that own company stock include Barbara Gayle Duncan, Elizabeth Trehu, Hugh M Cole, John Duncan Higgons, Kevin C Tang, Kimberlee C Drapkin, Richard /Ca/ Murray, Rock Ventures Ii LP Third and Rock Ventures Iii LP Third. View institutional ownership trends. How do I buy shares of Jounce Therapeutics? Shares of JNCE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Jounce Therapeutics' stock price today? One share of JNCE stock can currently be purchased for approximately $1.52. How much money does Jounce Therapeutics make? Jounce Therapeutics (NASDAQ:JNCE) has a market capitalization of $79.25 million and generates $82 million in revenue each year. The company earns $-50,920,000.00 in net income (profit) each year or ($2.56) on an earnings per share basis. How many employees does Jounce Therapeutics have? The company employs 137 workers across the globe. How can I contact Jounce Therapeutics? Jounce Therapeutics' mailing address is 780 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The official website for the company is www.jouncetx.com. The company can be reached via phone at (857) 259-3840 or via email at mdeon@jouncetx.com. This page (NASDAQ:JNCE) was last updated on 3/23/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.